tion, imaging studies, procedural notes, percentage of tu mor devascularization, and endovascular complications were evaluated. The institutional review board at the Uni versity of Miami approved the study.
Embolization Technique
Our technique for tumor embolization with Onyx has been described elsewhere. 4 All embolizations were performed with the patient under general anesthesia. Pre embolization angiograms were obtained following per cutaneous femoral arterial catheterization. Images were analyzed to determine the extent of tumor blush. Intrave nous heparin was administered to maintain activated clot ting times between 250 and 300 seconds. A 5Fr catheter (Envoy, Cordis Corp.) was positioned in the external ca rotid branch that fed the tumor. Selective catheterization of the feeding vessels was subsequently performed using a Marathon microcatheter (eV3 Inc.). A microangiogram was then obtained to assess the tumor blush supplied by the feeding artery as well as the presence of dangerous ex tracranial to intracranial anastomoses. Dead space within the microcatheter was slowly flushed with 0.3-0.4 ml di methyl sulfoxide. Onyx embolization was then performed under a subtracted roadmap. The grade of Onyx selected was based on the rapidity of flow demonstrated on the pre embolization angiogram and the desired degree of Onyx penetration within the tumor parenchyma. The standard technique for Onyx embolization was used until the de sired degree of tumor penetrance or the maximal degree of reflux along the microcatheter was reached. Emboliza tion of other feeding pedicles then proceeded in a similar manner as necessary. Once embolization was completed and the microcatheter was removed, a final postemboliza tion arterial angiogram was obtained to assess the degree of tumor devascularization and to ensure that there was no inadvertent embolization into the cerebral vasculature.
Evaluation of Angiographic Devascularization
Determining if there was intraparenchymal penetra tion of Onyx was based on whether the embolic agent reached the tumor capillary bed or remained in the feed ing arterial pedicle. The percentage of tumor devascular ization was determined by tracing the pre and postembo lization tumor blush using ImageJ software (version 1.41, National Institutes of Health). The ratio of post and pre embolization tracing in pixels was then calculated. 4 
Results
Over a 6year period, 11 patients with glomus jugulare tumors underwent preoperative embolization with Onyx (Table 1 ). All embolization procedures were completed in a single session. The mean fluoroscopy time was 83 min utes (range 40-157 minutes). The mean volume of Onyx used was 4.9 ml (range 1.7-10 ml). Twentythree vessels were selectively catheterized for embolization. Eight pa tients required selective embolization via multiple vessels, and 8 required embolization via the ascending pharyngeal artery. All but 2 patients underwent embolization with lowerviscosity Onyx 18. Migration of Onyx within the tu mor parenchyma was achieved in all cases. There was no evidence of nontarget embolization. The mean percent of tumor devascularization was 90.7%. The mean time from embolization to surgery was 3.1 days (range 1-7 days). The mean followup was 30 months (range 4-72 months). Two cases (18%) of cranial neuropathy were attributed to the embolization procedures; one patient suffered perma nent facial paralysis, and another developed permanent lower cranial nerve dysfunction.
Illustrative Cases

Case 5
A 35yearold woman presented with a 1year his tory of rightsided pulsatile tinnitus and hearing loss. The mass was biopsied at an outside clinic, resulting in copious bleeding. An angiogram showed a vascular tumor blush fed by multiple small vessels from the right ascend ing pharyngeal, middle meningeal, and posterior auricular arteries as well as a large aberrant feeding vessel arising from the cervical internal carotid artery (ICA; Fig. 1A ). The patient underwent superselective catheterization of the large ICA feeder (Fig. 1B) followed by embolization using 4.5 ml of Onyx 18. Final postembolization angiog raphy demonstrated 90% tumor devascularization with marked intraparenchymal Onyx penetration (Fig. 1C) . No evidence of nontarget embolization was seen. The patient woke up from the procedure with complete facial paraly sis on the right side. Seven days after embolization, the tumor was completely resected via a subtotal petrosec tomy with facial nerve decompression. At surgery, Onyx material was observed tracking along the facial nerve and its vasa vasorum (Fig. 1D ). Final pathological results were consistent with a glomus tumor. The patient had not recov ered any facial nerve function at the 6month followup.
Case 10
A 45yearold woman presented with leftsided hear ing loss and tinnitus. Further workup demonstrated a "salt and pepper" mass in the jugular foramen on MRI and pos itive uptake on an octreotide scan. Angiography showed a vascular tumor blush fed primarily by vessels from the occipital and ascending pharyngeal arteries (Fig. 2 left) . Selective catheterization and embolization of ascending pharyngeal and occipital artery feeders were performed using 2.5 ml of Onyx 18. The final postembolization an giogram demonstrated complete tumor devascularization (Fig. 2 right) . The patient experienced postprocedural ipsi lateral shoulder weakness and hoarseness. Uneventful sur gical removal was performed 5 days later. Pathology was consistent with a glomus tumor. The postembolization deficit did not resolve after 9 months of clinical follow-up.
Discussion
Onyx is a nonadhesive, liquid embolic agent approved by the FDA in 2005 for the treatment of cerebral arte riovenous malformations. The unique properties of Onyx, which have been discussed by Gore et al., facilitate its penetration into the deep vasculature. 7 The effectiveness of Onyx in the treatment of cerebral vascular malforma tions has encouraged its offlabel use for tumor emboliza tion. We previously detailed our experience utilizing Onyx for the embolization of various head, neck, and spinal tu mors. 4 However, we recently noted 2 instances of perma nent cranial nerve complications following Onyx emboli zation of glomus jugulare tumors even though the embolic material remained within the confines of the tumor blush and despite the absence of nontarget embolization or sig nificant reflux in the feeding artery. Upon review of our series, we were surprised that 18% of the patients with glomus jugulare tumors had suffered permanent cranial nerve morbidity following embolization.
There is limited experience with the preoperative em bolization of glomus jugulare tumors using Onyx. To our knowledge, this is the second report of permanent cranial neuropathy following superselective embolization of these lesions with Onyx. We provide a summary of previously documented cranial nerve complications due to preopera tive embolization in Table 2 . Gartrell et al. highlighted the potential risk of this procedure in their series of 3 patients with postembolization cranial neuropathy. 5 They attribut ed the increased risk of embolization to anatomical varia tions in the cranial nerve blood supply. Another possible explanation is based on the frequently shared external ca rotid artery blood supply between glomus jugulare tumors and the vasa nervosa of the cranial nerves, which renders them vulnerable to occlusion with Onyx during emboliza tion. 2, 13 Several potential strategies can enhance the safety of embolization for glomus jugulare tumors: defining the goal of embolization, using particulate embolics, or embolizing by direct puncture. It has been suggested that the goal of embolization should be occlusion of the capil lary bed of the tumor parenchyma. 7, 8 Furthermore, there is some evidence that tumor embolization without intra parenchymal penetration of the embolic material may not optimally reduce intraoperative blood loss. 4 Without ar resting flow through the parenchymal capillary bed, oc clusion of only the feeding artery pedicles may result in persistent tumor vascularity, especially if not all pedicles are embolized. However, given the absence of definitive evidence that parenchymal embolization is the only effec tive method of reducing blood loss and the high incidence of cranial neuropathy associated with Onyx embolization of glomus jugulare tumors, perhaps the goal of emboli zation should be pedicular occlusion with minimal reflux along the feeding artery.
There appears to be a lower risk of permanent cranial neuropathy following embolization of glomus jugulare tu mors by using particulate embolics. LaRouere et al. found no significant complications in a series of 4 patients em bolized with polyvinyl alcohol (PVA). 10 These findings are corroborated by a larger study by White et al. 19 in which 8 of 38 patients embolized with PVA had glomus jugulare tumors, and none experienced major complications. Par ticles ranging in size from 150 to 1000 mm were used in these studies. To our knowledge, only 4 cases of cranial nerve palsy from PVA have been reported since the 1980s, and all resolved. 9, 11, 18, 19 The low incidence of cranial nerve morbidity can be explained by the use of large particles that typically do not reach the vasa nervosa. Furthermore, because particulate embolics are known to dissipate over time, cranial neuropathies noted following PVA emboliza tion have tended to recover, because of early recanalization of branches feeding the cranial nerves. [9] [10] [11] 15, 19 Although recanalization of the tumor can also occur, it is generally not a concern, especially if the resection is performed in a timely manner after embolization. On the other hand, Onyx is believed to result in more permanent occlusion of the vasculature, which may explain the permanency of cranial nerve palsies. Although we cannot make definite conclusions regarding the influence of Onyx viscosity on the development of postembolization cranial nerve ische mia, both of the neuropathies encountered in our series occurred with the use of the lowerviscosity Onyx 18. One could hypothesize that just as the smaller particles of PVA have been associated with a higher incidence of nerve is chemia, the less viscous formulation of Onyx may also have a greater tendency to occlude the vasa nervosa.
An alternative to transarterial embolization is direct percutaneous intratumoral injection of embolic material. This approach was first reported by Casasco et al. using Nbutyl cyanoacrylate (NBCA) in a series that included 2 glomus tumors. 1 Ozyer et al. described 10 patients, 3 with glomus jugulare tumors, who underwent direct intratu moral embolization using Onyx, PVA, or NBCA without complication.
14 Spelle et al. have also documented success ful percutaneous embolization of glomus jugulare tumors with combined CT and fluoroscopic imaging guidance; however, complications were not explicitly mentioned. 17 In our previously reported series of direct puncture embo lizations for vascularized head and neck tumors, no per manent cranial nerve palsies were observed. 3 Although no cases of cranial nerve palsies related to direct tumor embolization have been reported, glomus jugulare tumors constituted a minority of lesions in these series. There fore, larger studies are needed to validate the safety and superiority of this technique as compared with standard transarterial embolization.
Conclusions
Embolizing glomus jugulare tumors with Onyx can produce a dramatic reduction in tumor vascularity. How ever, the intimate anatomical relationship and overlapping blood supply between glomus jugulare tumors and cranial nerves may contribute to a high incidence of cranial neu ropathy following Onyx embolization.
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